Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in September 2011 on request of the Sponsor.

On 5 December 2001, orphan designation (EU/3/01/073) was granted by the European Commission to NeuTec Pharma plc, United Kingdom, for recombinant human monoclonal antibody to hsp90 for the treatment of invasive fungal infections.

The sponsorship was transferred to Novartis Europharm Limited, in June 2007.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Recombinant human monoclonal antibody to hsp90
Disease / condition
Treatment of invasive fungal infections
Date of first decision
EU designation number

Sponsor's contact details

Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
Tel. +41 61 324 11 11 (Switzerland)

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating